Report generated with Calculate by QxMD at https://www.qxmd.com/calculate
Over 400 decision support tools available • get the app for iOS or Android at qx.md/calculate
Patients with monoclonal gammopathy of undetermined significance (MGUS) have an increased risk of developing a hematologic malignancy, most often multiple myeloma from IgG and IgA MGUS, and other malignant lymphoproliferative disorders from IgM MGUS. A previous large study from the Mayo Clinic of patients in Minnesota with MGUS detected an overall risk of progression of approximately 1% per year (Kyle 2002). This model from the same Minnesota population proposes a risk-stratification model based on serum M-protein concentration, type of paraprotein, and presence of an abnormal serum free kappa:lambda light chain ratio (Rajkumar 2005). This risk-stratification model may be useful in identifying MGUS patients with a high risk of progression as candidates for closer supervision and potential clinical trial strategies. It may also prove useful in identifying patients with a very low risk of malignant transformation and less intensive follow-up (BCSH MGUS Guidelines), although surveillance strategies based on this model require prospective study.
References
This model was developed by Rajkumar et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005 Aug 1;106(3):812-817.
View Abstract
The original Mayo Clinic determination of MGUS risk of progression was reported by Kyle et al. A long-term study of prognosis of monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-569.
View Abstract
Guidelines for the initial investigation and management of MGUS have been published by Bird et al. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): Guidelines for the investigation of newly detected M-proteins and the management of Monoclonal Gammopathy of Undetermined Significance (MGUS) - accessed June 13, 2009.
View Guidelines
Do you have an enquiry or suggestion? Get in touch with us through Twitter @QxMD, Facebook QxMD, or email [email protected]